Pliant Therapeutics

General Information


We are a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Our initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ß. We have applied our deep understanding of fibrosis biology, along with our medicinal chemistry and translational medicine expertise to develop a set of proprietary tools designed to discover and de-risk product candidates quickly and efficiently. Our wholly-owned lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that we are developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.

Employees: 62
Founded: 2015
Contact Information
Address 260 Littlefield Avenue, South San Francisco, CA 94080, US
Phone Number (650) 481-6770
Web Address
View Prospectus: Pliant Therapeutics
Financial Information
Market Cap $547.2mil
Revenues $85.99 mil (last 12 months)
Net Income $8.5 mil (last 12 months)
IPO Profile
Symbol PLRX
Exchange NASDAQ
Shares (millions): 9.0
Price range $16.00 - $16.00
Est. $ Volume $144.0 mil
Manager / Joint Managers Citigroup/ Cowen and Company/ Piper Sandler
CO-Managers Needham & Co.
Expected To Trade: 6/3/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change